KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Gross Profit (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Gross Profit data on record, last reported at $929.4 million in Q2 2025.

  • For Q2 2025, Gross Profit rose 1.7% year-over-year to $929.4 million; the TTM value through Jun 2025 reached $3.7 billion, up 7.18%, while the annual FY2025 figure was $3.8 billion, 3.89% up from the prior year.
  • Gross Profit reached $929.4 million in Q2 2025 per JAZZ's latest filing, down from $959.5 million in the prior quarter.
  • Across five years, Gross Profit topped out at $959.5 million in Q4 2024 and bottomed at $567.4 million in Q1 2021.
  • Average Gross Profit over 5 years is $807.3 million, with a median of $807.0 million recorded in 2022.
  • Peak YoY movement for Gross Profit: increased 27.83% in 2022, then increased 1.7% in 2025.
  • A 5-year view of Gross Profit shows it stood at $760.6 million in 2021, then increased by 5.81% to $804.8 million in 2022, then grew by 12.42% to $904.7 million in 2023, then increased by 6.05% to $959.5 million in 2024, then dropped by 3.13% to $929.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $929.4 million in Q2 2025, $959.5 million in Q4 2024, and $943.4 million in Q3 2024.